Summary
Agilent is a leading provider of life sciences tools with strong innovation capabilities. While facing margin pressures, its installed equipment base and exposure to defensive healthcare spending provide stability. Valuation appears rich relative to near-term risks.
Bull Case
Agilent’s new product pipeline and 70% recurring revenue base position it to capitalize on global healthcare digitization. With analysts forecasting $136.82 target (15% upside), its leadership in precision diagnostics could drive multiple expansion as trade tensions ease.
Bear Case
Margin compression from tariff costs and slowing pharma capex could derail growth. At 29x P/E, any earnings miss would punish the stock. High debt load limits flexibility in a rising rate environment.
Recent News
- Unveiled Hybrid Multisampler and LC Single Quadrupole Mass Spectrometers at HPLC 2025 Conference (Source)
- Q2 2025 revenue beat estimates at $1.67B (+6% YoY) but net income fell 30% YoY (Source)
- Raised full-year earnings guidance despite tariff risks (Source)
- International revenue streams under scrutiny amid global trade tensions (Source)
Financial Analysis
- Revenue growth slowing: 6% YoY in Q2 2025 vs 7.8% YoY in Q4 2024
- Margin compression: Operating margin fell from 23.1% (Q2 2024) to 18% (Q2 2025)
- R&D investment stable at ~$110M/quarter (1.1-1.3% of revenue)
- Net debt/EBITDA ratio increased to 5.55x in Q2 2025 from 1.94x in Q2 2024
- Elevated valuation: P/E 29.3 vs industry avg ~25, P/S 5.1 vs sector median 3.2
- Declining ROIC: 2.48% in Q2 2025 vs 3.70% in Q2 2024
- Strong liquidity: Current ratio 2.09, Quick ratio 1.27 (Q2 2025)
- Dividend sustainability: 0.85% yield with 21% payout ratio (Q2 2025)
While Agilent shows revenue growth in diagnostics sector (6% YoY), margin pressures from tariff risks (US-EU tensions) and R&D costs are evident. The 5.1x P/S ratio suggests market expects premium growth despite global trade contraction (WTO forecasts -0.2% goods trade). High beta (1.23) indicates sensitivity to market swings amid Fed policy uncertainty.
Screener Ratings
Compare over 5500 companies with our screener ratings at AIpha.io.
Overall: 7
Quality business facing cyclical headwinds, appropriate for growth-oriented investors with 3-5 year horizon
Value: 6
Premium valuation (29.3 P/E) prices in growth that may be challenged by macro headwinds
Growth: 7
5.3% core revenue growth supported by new product launches but tempered by margin trends
Dividend: 4
0.85% yield below sector average, though sustainable given low payout ratio
Defensive: 7
Healthcare sector exposure provides stability but cyclical instruments business adds risk
Moat: 8
Strong IP portfolio and switching costs in diagnostics equipment
S.W.O.T. Analysis
Strengths:
- Market leader in LC/MS systems
- Recurring revenue (70% from services/consumables)
- Strong balance sheet ($1.5B cash)
Weaknesses:
- Declining operating margins
- High exposure to China (25% sales)
- Debt/EBITDA of 5.5x
Opportunities:
- Expanding into emerging markets
- AI-driven diagnostic demand
- Post-tariff trade normalization
Threats:
- US-EU tariff escalation
- Pharma R&D budget cuts
- Supply chain disruptions
Industry Overview
Threat of New Competitors: High barriers: Capital-intensive R&D ($450M annual) and regulatory approvals limit new competitors
Competition Among Existing Firms: Intense: Competes with Danaher, Thermo Fisher in $60B life science tools market
Suppliers’ Bargaining Power: Moderate: Specialized component suppliers but diversified manufacturing base
Buyers’ Bargaining Power: High: Large pharma/biotech clients demand customized solutions
Threat of Substitute Products: Low: Proprietary lab equipment has few alternatives
Competitive Advantage
Cost Advantage: Scale in diagnostics R&D (14% gross margin premium vs peers)
Intangible Assets: 9,000+ patents and strong brand in mass spectrometry
Network Effect: Installed base of 50,000+ instruments drives consumables sales
Switching Costs: High: Lab workflow integration creates lock-in (DSO 235 days)
Warning: This document has been generated by an advanced customised AI prompted with financial data derived from company filings and other reputable sources. The process is specifically designed to minimise hallucinations, however the output is not 100% reliable. It is essential to check any information in this document before relying on it for financial decisions. You can find the underlying data used here.
Legal Disclaimer
The information contained on this website and associated documents, including all text, data, analyses, opinions, and forward-looking statements, is provided solely for general informational purposes and does not constitute financial, investment, legal, or tax advice. The content has been generated by an artificial intelligence tool using publicly available data and company filings. Although every effort has been made to ensure accuracy, the information is provided “as is” without any warranty—express or implied—of completeness, accuracy, reliability, or suitability for any purpose.
Not Regulated Advice
No FCA Authorization: We are not authorized or regulated by the Financial Conduct Authority (FCA) or any other financial regulatory body to offer investment advice or recommendations. Nothing in this report should be construed as a solicitation, recommendation, or endorsement to buy, sell, or hold any security or financial instrument.
Independent Decision-Making: Investors are strongly encouraged to conduct their own research and consult with a licensed financial advisor or other professional before making any financial decisions. Reliance on the information provided herein is solely at your own risk.
Forward-Looking Statements
This report may contain forward-looking statements, which are based on current expectations, assumptions, and projections that involve risks and uncertainties. Actual results may differ materially from those expressed or implied by these statements. We do not undertake any obligation to update or revise any forward-looking statements in light of new information or future developments.
Limitation of Liability
Under no circumstances shall Aipha.io or its affiliates, employees, or agents be liable for any direct, indirect, incidental, consequential, or other damages arising out of or in connection with the use of, or reliance on, the information contained in this report—even if advised of the possibility of such damages. This includes, without limitation, any loss of profit, revenue, or data.
Use at Your Own Risk
By using this report, you acknowledge that you have read and understood this disclaimer and agree that any reliance on the information provided is at your own risk. [Your Company Name/Aipha.io] expressly disclaims any and all liability for any loss or damage of any kind incurred as a result of any use of this report.